

TROG 2024

Together Towards Tomorrow

DELEGATE
HANDBOOK



36th TROG Cancer Research Annual Scientific Meeting
12 - 15 March 2024 | Newcastle NSW

TROG | CANCER
RESEARCH

EVENT PARTNER & WORKSHOP SPONSOR

varian

A Siemens Healthineers Company

PLATINUM SPONSORS




GOLD SPONSOR



SOCIAL FUNCTION SPONSORS



BRONZE SPONSORS



SESSION SPONSOR



MARK HUGHES
FOUNDATION
CENTRE FOR
BRAIN CANCER
RESEARCH

WORKSHOP SESSION SPONSORS





Table of Contents

DELEGATE INFORMATION.....	5
VENUES.....	5
SOCIAL PROGRAM.....	5
MOBILE PROGRAM & WIFI	6
SPEAKER PRESENTATION INSTRUCTIONS	6
POSTER PRESENTATION INSTRUCTIONS	6
KEYNOTE SPEAKERS	8
INVITED SPEAKERS	8
PROGRAM.....	13
Tuesday 12 March 2024	13
Wednesday 13 March 2024	17
Thursday 14 March 2024.....	21
Friday 15 March 2024	25
POSTER LISTING.....	28
SPONSOR & EXHIBITOR PROFILES	29

Attend and win prizes!

Go in the draw to win some great prizes, simply by visiting the exhibitors in the Concert Hall.

When you collect your name badge you'll receive your passport card (below). Obtain a stamp from each exhibitor, enter your details on the back and hand it to the registration desk staff.

The prize draw will occur during the closing comments on Friday 15 March.



CONFERENCE SECRETARIAT

ASN Events Pty Ltd

9/37 Smith Street

Fitzroy, VIC 3065, Australia

Contact person on-site:

Chris Dayson | M: +61 (0)413 608 373 | email: chris.d@asnevents.net.au



ARIA CORE



Finally, a complete **continuum of care** for all of oncology.

One solution. Endless possibilities. The single, seamless, connected system to actively manage patient information and drive workflows—**a new dimension in oncology care.**

varian
A Siemens Healthineers Company

Refer enquiries to Varian Medical Systems Australasia on 1800.657.036 or customerservice-anz@varian.com





DELEGATE INFORMATION

VENUES

SCIENTIFIC MEETING

Newcastle City Hall
290 King St, Newcastle

GALA DINNER

NEX (Newcastle Entertainment & Conference Centre)
309 King St, Newcastle West

CREW & TRW WORKSHOPS

Peibri Place
97 Hannell St, Wickham

CREW & SMART WORKSHOPS

Newcastle Cruising Yacht Club (NCYC)
95 Hannell St, Wickham

WORKSHOPS

Technical Research Workshop (TRW)

9:00am - 5:00pm - Peibri Place

Statistical Methods, Evidence Appraisal & Research for Trainees Workshop (SMART)

8:30am - 6:00pm - NCYC

Clinical Research Education Workshop (CREW)

9:00am - 11:00am - Peibri Place

11:00am - 5:00pm – NCYC

REGISTRATION DESK

The registration desk will be open as followings:

Wednesday 13 March 7:15 AM – 7:00 PM

Thursday 14 March 7:15 AM – 5:00 PM

Friday 15 March 8:30 AM – 1:00 PM

DIETARY REQUIREMENTS

Workshops

Served on a separate table in the catering space of your respective venue. Ask staff for directions.

Scientific Meeting

Served on a separate table in the Concert Hall. Ask staff for directions.

Gala Dinner

Upon arrival collect your dietary requirement table card at the entrance and place it in front of you at your table.

SOCIAL PROGRAM

All delegates are invited to attend the social functions however pre-registration is required. If your name badge does not include a ticket for these events and you would like to purchase one for yourself and/or someone else, please see the ASN staff at the registration desk about availability.

Welcome Reception

Date: Wednesday 13 March
Time: 5:30 pm – 7:30pm
Location: Newcastle City Hall

Gala Dinner

Date: Thursday 14 March
Time: 7:00 pm – 11:00pm
Location: The NEX

Theme: Black tie on the beach



MOBILE PROGRAM & WIFI

For easy access to the Meeting program, event information, exhibitor details, and note taking, open the Mobile Program using the QR code.

Newcastle City Hall

Server: TROG Meeting 2024

Password: TROG2024




SPEAKER PRESENTATION INSTRUCTIONS

All plenary sessions take place in the Banquet Room. Audio-visual equipment will be supplied and there will be a technician on site to assist with any enquires. **Please make sure your presentation is in 16:9 format** to get the best image. All presentations must be pre-loaded onto the AV laptop prior to the session commencing. Please bring your presentation on a USB drive to the Banquet room during the break prior to your session. A presenter's tool (clicker) will be provided at the lectern.

POSTER PRESENTATION INSTRUCTIONS

Posters should be size A0 portrait orientation and can be attached to the poster boards with Velcro. Additional Velcro supplies can be obtained from the registration desk. The poster boards are located in the Concert Hall and numbered according to the Poster Listing in this handbook.

EXHIBITION FLOOR PLAN & EXHIBITOR LISTING



Booths 1 & 2 – Elekta

Booth 3 – TROG

Booth 6 – alphaXRT

Booth 7 – ACDS

Booth 8 – AIQ Solutions

Booth 10 – Brainlab

Booth 11 – Cipla

Booth 12 – Mundipharma

Booth 13 – Oxford Scientific

Booth 14 – Icon Centre

Booths 15 & 16 - Varian



World-class cancer care, close to home

Radiation Oncology | Medical Oncology |
Haematology | Clinical Trials



40+ years experience delivering cancer care



38 cancer centres [and growing]



200+ internationally recognised specialists



Australia's largest private cancer clinical trials program



No wait list for consultation or treatment

Icon Cancer Centre is part of Icon Group - Australia's largest dedicated cancer care provider. Our mission is strong but simple - to deliver the best cancer care possible, to as many people as possible, as close to home as possible.



KEYNOTE SPEAKERS



Prof. Stephen Kry

The University of Texas MD Anderson Cancer Centre, USA

Dr. Stephen Kry is a board-certified tenured professor at The University of Texas MD Anderson Cancer Center where he serves as director and principal investigator of the National Cancer Institute's Imaging and Radiation Oncology Core and ensures the highest quality data for clinical trials.

He also serves as director of the Radiation Quality Assurance Laboratory and an Accredited Dosimetry Calibration Laboratory. Dr. Stephen Kry has extensive independent funding, more than 150 peer reviewed publications, and has mentored more than 40 graduate students. He is also a native Canadian and avid skier and hiker.



Prof. Stephane Supiot

Institut de Cancérologie de l'Ouest, University of Nantes, France

Prof. Stéphane Supiot is a clinician Scientist in the Department of Radiation Oncology at Institut de Cancérologie de l'Ouest, University of Nantes, France.

Prof. Supiot's interests are in developmental therapeutics for pediatric and prostate cancer radiotherapy. His preclinical research interests are hypoxic response modifiers and the vascular response to irradiation.

His clinical areas of research involve biochemically relapsing and oligometastatic prostate cancer. He is principal investigator on several clinical studies in the Groupe d'Etude des Tumeurs Uro Genitales-GETUG group, such as Oligopelvis GETUG P07, Oligopelvis 2 GETUG P12, POSTCARD GETUG P13, CARLHA GEP 12, CARLHA 2 GETUG 33.

INVITED SPEAKERS



Dr Gerry Adams

Dr Gerry Adams is a UK trained clinical oncologist who arrived in Australia in 2010. After completing his Fellowship he has worked as a consultant in regional Queensland for 9 years and was involved in various positions within the Royal Australian and New Zealand College of Radiologists (RANZCR) during that time.

For the last 3 years he has been a member of RANZCR Council and Chair of the Economics and Work Force Committee (EWC). As RANZCR Dean Gerry's position on the Board of Directors of TROG will help maintain the important strategic links and shared values of our two organisations.

Gerry has a particular interest in improving access to quality radiation therapy in regional areas.



A/Prof Haryana Dhillon

Associate Professor Haryana Dhillon (BSc MA PhD) is a Senior Research Fellow, who co-leads the Survivorship Research Group at the University of Sydney. They chair the Scientific Advisory Committee of the Psycho-Oncology Cooperative Research Group.

Haryana has more than 25 years experience in cancer clinical research across a range of investigator-initiated cancer clinical trials. Their research interests are broad encompassing cancer survivorship, health literacy, and interventions for survivorship, symptom management, and psycho-oncology.

Haryana is passionate about rigor in research, practical solutions to tricky problems, and doing what she can to help humans make it to the 22nd century.



Dr Harriet Gee

Dr Harriet Gee is a Staff Specialist in the Department of Radiation Oncology, Westmead Hospital, Sydney. She holds an MBBS/B Med Sci (First Class Honours), from the University of Melbourne, and a DPhil in Molecular Oncology from the University of Oxford, where she studied as a Rhodes Scholar.

As well as clinical practice serving patients with thoracic cancer, she is actively engaged in translational research, co-leading a research program examining cell death after ablative radiotherapy. Dr Gee teaches medical students and advanced trainees and has been involved in curriculum development for the RANZCR.



Dr Fiona Hegi-Johnson

Dr Fiona Hegi-Johnson is a Radiation Oncologist at the Peter MacCallum Cancer Centre in Victoria and Senior Research Fellow at the University of Melbourne.

Clinically, she specialises in the treatment of patients with lung and breast cancer, including a subspecialty interest in stereotactic ablative body radiotherapy (SABR). Fiona is also the Chair of the TROG Lung Subspecialty Group and is the chief investigator on a number of clinical trials in lung cancer.

Fiona's research programme, which is supported by a Victorian Cancer Agency Fellowship, focuses on developing and using novel PET tracers to integrate biological and imaging information into radiotherapy to develop personalized, biologically driven approaches to radiotherapy treatment.



Dr Deme Karikios

Dr Deme Karikios is a medical oncologist at Nepean Hospital in Sydney. He has a clinical and research interest in thoracic and gastrointestinal malignancies.

Deme also has a research interest in costs and value of anticancer drugs, decisions about treatment with expensive unsubsidised anticancer drugs and financial toxicity. He was awarded his PhD in 2019, entitled “The consequences of rising anticancer drug costs in Australia” which he undertook at the NHMRC Clinical Trials Centre, University of Sydney.

Deme is a founding member of the Common Sense Oncology movement and active member of the COSA Financial Toxicity Working Group.

Deme is a co-supervisor of several PhD students and is a senior clinical lecturer at the University of Sydney. Deme has an interest in cancer care policy and is the immediate past chair of the Medical Oncology Group of Australia.



A/Prof Michael Jameson

Assoc. Prof. Michael Jameson FRACP FRCP (Edin.) PhD is Co-director of Cancer Trials New Zealand (CTNZ) based at the University of Auckland, Assistant Dean at the Waikato Clinical Campus, Faculty of Medical and Health Sciences, University of Auckland, and Medical Oncologist at Waikato Hospital, Hamilton. His main research interests gravitate towards collaborative investigator-initiated clinical trials and translational research, including repurposing drugs in oncology. As Co-director of CTNZ since 2022 he works with a team focussed on supporting clinical and scientific researchers to develop investigator-initiated clinical and translational research projects, gain grant funding, and conduct those trials at multiple sites. He is leading a CTNZ project to develop a formal national cancer trials network in New Zealand, aligning with the “Enhancing Aotearoa New Zealand Clinical Trials” project.

This includes a focus on strategies to improve equitable access to clinical trials, which includes developing the clinical research workforce and infrastructure, especially in smaller regional and rural communities. CTNZ collaborated with government agencies, industry bodies and other researchers to successfully develop standard operating procedures for decentralised trials in New Zealand, with such trials now underway.



Dr Susanne Rogers

Susanne Rogers qualified at the University of Cambridge, UK and undertook general medical training and subsequently clinical oncology training in London, UK. She undertook research focusing on targeted EGFR inhibition in head and neck cancer at The Royal Marsden Hospital / Institute of Cancer Research and was awarded a PhD in 2010.

Since then, she lives and works in Switzerland, where she is deputy head of radiotherapy at Kantonsspital Aarau.

Her current clinical and research interests include radiotherapy and radiosurgery for the treatment of primary and secondary brain tumours.

Hope for everyone
dealing with cancer.



Experience the freedom of the most comprehensive radiation therapy ecosystem from Elekta—adaptive, precise and personalized for you, your patients and your practice.

We don't just build technology, **we build hope**






elekta.com



PROGRAM



Tuesday 12 March 2024 Clinical Research Education Workshop (CREW) PROGRAM

09:00 - 10:30	Joint CREW & TRW Session	Peibri Place
09:00	Susan Goode Welcome	Sponsored by: 
09:05	Tanya Symons 1. Key changes in the draft of ICH E6 (R3) and the forthcoming Annexe 2 2. Changes in the 2023 National Statement relevant to RCTs	
10:30 - 11:00	Morning Tea	
11:00 - 12:30	Welcome Chairs: Bianca Karle & Kelly Skelton	Newcastle Cruising Yacht Club
11:05	Tanya Symons ICH-GCP E6 (R3) Workshop	
12:30 - 13:30	Lunch	
13:30	Sarah Lukeman From Start to Finish: Meaningful Health Consumer Involvement in Clinical Research	
14:45	Sarah Lukeman Gillian Mason Murray McLachlan Sue McCullough Panel Discussion	
15:30 - 16:00	Afternoon Tea	
16:00 - 17:00	Terri Davies Empowering Trial Sites: Strategies for ICH-GCP Adherence with optimal Data Integrity and Quality	Sponsored by: 

Notes



Tuesday 12 March 2024 Technical Research Workshop (TRW) PROGRAM

09:00 - 10:30	Session A: On your marks, get set, go!	Peibri Place
09:00	Susan Goode Welcome	Sponsored by:  
09:05	Tanya Symons Good Clinical Practice (GCP) and clinical research essentials.	
10:30 - 11:00	Morning Tea	
11:00 - 12:30	Session B: 'Citius, Altius, Fortius' (Faster, higher, stronger) Chairs: Ms. Jenna Dean & Mr. Fahim Siddiqi	
11:00	Jenna Dean & Mr. Fahim Siddiqi Let the games begin. Welcome to the Technical Research Workshop.	
11:05	Sean Watson Sponsor Address: Varian	
11:10	Prof. Stephen Kry It's not whether you win or lose, it's how you play the game. Keynote speaker: The power of data and data sharing.	
11:40	A/Prof. Chris Oldmeadow Gold medals are made in training, but champions are made in character. I want to do research! Where should I start?	
12:10	Alisha Moore No pain, no gain! Research opportunities - what data does TROG have and how can I use it?	
12:30 - 13:30	Lunch	

Notes



13:30 - 15:00	<p>Session C: Beyond the Podium: Where Dreams Take Flight Chairs: Ms Lucy Sim & A Prof. Nick Hardcastle</p>
13:30	<p>A Prof Nick Hardcastle Every four years, the world stops to watch ordinary people do extraordinary things. The big questions in research and embracing challenges.</p> <p>Panel Discussion Prof. Tomas Kron A/Prof. Chris Oldmeadow Dr. Sweet Ping Ng Prof. Stephen Kry Dr. Katrina Woodford</p>
14:20	<p>A Prof. Lois Holloway Let's light the Olympic flame.</p> <p>Frontiers in automation: overview, application and opportunities in research.</p>
14:40	<p>Prof. Paul Keall Hypofractionation – a win for patients and the health system. But what are the implications with regard to image guidance and accuracy?</p>
15:00 - 15:30	<p>Afternoon Tea</p>
15:30 - 16:55	<p>Session D: Winning is great, but the journey is where the real Olympians are made Chair: Ms Jenna Dean & Mr. Rob McDowall</p>
15:30	<p>Hands on session No false starts here – it's time for the final race. Hands on Session: How to develop your research idea.</p>
16:15	<p>Hands on session Go for gold! Hands on Session: Group presentations and discussion.</p>
16:35	<p>Prof. Tomas Kron One for the record books! Let's hear from the expert: Research development and conduct.</p>
16:55 - 17:00	<p>Jenna Dean & Fahim Siddiqi Closing remarks & survey completion</p>

TRW Workshops Sponsor

varian

A Siemens Healthineers Company




Tuesday 12 March 2024 Statistical Methods, Evidence Appraisal & Research for Trainees Workshop (SMART) PROGRAM

08:30 - 08:50	Welcome A/Prof Puma Sundaresan – President, TROG Cancer Research	Newcastle Cruising Yacht Club
8:50	Study Design Cohort / case control Aspects of bias Phase 1 and phase 2 designs Randomised controlled trials Randomisation and stratification Non-inferiority / equivalence designs	
09:30	Small Group Session 1	
10:30-10:50	Morning Tea	
10:50	Selecting endpoints Outcome to endpoint Endpoint selection Hazard ratios and Kaplan Meier	
11:10	Small Group Session 2	
12:00	International Guest speaker Professor Stephane Supiot, Institut de Cancérologie de l'Ouest, University of Nantes, France.	
12:30 - 13:30	Lunch	
13:30	Other issues Sample size considerations Non-compliance Confounders Appropriate follow up time Frequency of data collection Dealing with missing data	
14:25	Small Group Session 3	
15:25-15:45	Afternoon tea	
15:45	National Guest Speaker	
16:15	Critical appraisal wrap-up	
16:35	Closing comments	
17:00 – 18:00	Networking function	



Wednesday 13 March 2024

07:30 - 08:30	Catered Session Clinical Innovation for More Efficient Cancer Care Deepak Khuntia, MD, FASTRO	Banquet Room
Sponsored by:  A Siemens Healthineers Company		
9:00 - 10:30	Welcome & Official Opening Chairs: Joerg Lehmann & Jane Ludbrook	Banquet Room
09:00	Welcome to Country	
09:05	Official Welcome - Councillor Dr Elizabeth Adamczyk, City of Newcastle, Lord Mayor’s Office	
09:10	President's Report - Prof Trevor Leong	
09:20	TROG Scientific Committee Report - A/Prof Sasha Senthil	
09:30	TROG Independent Data and Safety Committee - Prof Bryan Burmeister	
09:35	International Keynote Address Stéphane Supiot Vascular remodelling during radiotherapy at low and ultra-high dose rate (Flash) <i>abs# 1</i>	
10:30 - 11:00	Morning Tea & Exhibition	Concert Hall

Notes



11:00 – 12:30		Plenary Session: Breast Chairs: Farshad Foroudi & Tomas Kron	Banquet Room
		Sponsored by:	
11:00	Farshad Foroudi & Tomas Kron Summary of TROG Breast portfolio abs# 2		
11:10	Emma Connolly Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR): A Phase II Prospective Multicentre Trial abs# 3		
11:20	Peter Graham PRELIMINARY RESULTS: TROG 08.06 STARS: A Randomised comparison of anastrozole commenced before and continuing during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy. (Cat A, Open) abs# 4		
11:30	Verity Ahern RESULTS TROG 12.02 PET LABRADOR: PET scans for locally advanced breast cancer and diagnostic MRI to determine the extent of operation and radiotherapy (Cat A, Open) abs# 5		
11:40	Claire Phillips Local HERO: A Phase II study of local therapy only (stereotactic radiosurgery and/ or surgery) for treatment of up to 5 brain metastases from HER2+ breast cancer. TROG 16.02 abs# 6		
11:50	Nicholas Zdenkowski The intersections between systemic and local therapy for breast cancer: current status and future opportunities abs# 7		
12:15	Peter Griffin Whole breast knowledge-based planning predictions and transferability: a transcontinental consortia experience abs# 8		
12:30 – 13:30			
		Catered Session Embracing Innovation and Enhancing Outcomes with Advanced Technology Deepak Khuntia, MD, FASTRO	Banquet Room
		Sponsored by:	
			



Notes




13:30 – 15:00	Plenary Session: Rural & Regional Chair: Patrick Horsley & Michael Penniment	Banquet Room
13:30	Michael Jameson Opportunities for extending cancer clinical trials to NZ rural and regional locations <i>abs# 9</i>	
13:50	Gerry Adams Enablers for the conduct of cancer clinical trials in rural and regional locations <i>abs# 10</i>	
14:10	Craig Underhill Learnings from the RTN-Vic and ReViTALISE initiatives: Enabling clinical trial participation across boundaries <i>abs# 11</i>	
14:30	Georgia Halkett Investigating Oncologists' attitudes towards the transition of patients to primary care for treatment follow-up <i>abs# 12</i>	
14:40	Panel Discussion: A/Prof Michael Jameson, University of Auckland; Dr Gerry Adams, Royal Australian and New Zealand College of Radiologists; Dr Craig Underhill, Albury Wodonga Health/North East Health; A/Prof Georgia Halkett, Curtin University	
15:00 – 15:30	Afternoon Tea, Exhibition & Poster Displays	Concert Hall

Notes



15:30 – 17:00 Plenary Session: Central Nervous System		Banquet Room
Chairs: Mark Pinkham & Kylie Jung		
		Sponsored by:
		 
15:30	Mark Pinkham Central Nervous System (CNS) Working Party update <i>abs# 13</i>	
15:35	Eng-Siew Koh The prospective, multi-centre trial evaluating FET-PET in Glioblastoma (FIG) study, TROG 18:06 - study update and current learnings <i>abs# 14</i>	
15:45	Neda Haghighi TD 23.02 Pre-operative radiosurgery for brain metastases (Cat A, In Development) <i>abs# 15</i>	
15:55	Frank Saran TD 23.02; Discussant <i>abs# 16</i>	
16:10	Susanne Rogers Pre-operative SRS for brain metastases; DEGRO perspective <i>abs# 17</i>	
16:30	Yu Yang Soon What are the next rad onc trials in brain metastases <i>abs# 18</i>	
16:40	Panel Discussion: Prof Frank Saran, Australian Bragg Centre; Dr Yu Yang Soon, National University Cancer Institute, Singapore; Dr Catherine Johnson, John Hunter Hospital; A/Prof Haryana Dhillon, University of Sydney A/Prof James Lynam, Calvary Mater Newcastle	

17:00 – 17:30 TROG Annual General Meeting (AGM)		Banquet Room
		Concert Hall
17:30 – 19:30	Welcome Reception	Sponsored by:
		

Notes



Thursday 14 March 2024

07:30 - 08:30	<p>Catered Session Unity MR-Linac Global Registry Collaboration and Clinical Update - ONJ Austin Health</p> <p>Sweet Ping Ng, MBBS, PhD, FRANZCR</p>	<p>Banquet Room</p> <p>Sponsored by: </p>
<p>09:00 - 10:30 Plenary Session: Genitourinary Banquet Room Chair: Wee Loon Ong & Niluja Thiru</p>		
<p>Sponsored by: </p>		
09:00	<p>Stéphane Supiot The GETUG Strategy of clinical trials in oligometastatic prostate cancer <i>abs# 19</i></p>	
9:20	<p>Shankar Siva FASTRACK - Multicentre Phase II Trial of SABR for Primary Kidney Cancer <i>abs# 20</i></p>	
9:35	<p>Shankar Siva TROG 19.06 DECREASE: Darolutamide + Consolidation Radiotherapy in Advanced proStatE cancer detected by PSMA (Cat A, Open) <i>abs# 21</i></p>	
9:40	<p>Jarad Martin TROG 18.01 NINJA: Novel Integration of New prostate radiation schedules with adjuvant Androgen deprivation (Cat A, Open) <i>abs# 22</i></p>	
9:45	<p>Wee Loon Ong TD 23.03 2SHOTS; 2-fraction Stereotactic radiotherapy Of the ProState (Cat A, New Proposal) <i>abs# 23</i></p>	
9:53	<p>Eric Wegener TD 23.03 2SHOTS: Discussant <i>abs# 24</i></p>	
10:05	<p>Muhammad Ali TD 23.01 REMASTER; REduced MArgin STEReotactic body radiotherapy for prostate cancer: A phase III randomised trial (Cat A, In development) <i>abs# 65</i></p>	
10:15	<p>Niluja Thiru TD 23.04 PEARLS A phase II/III trial of Primary radiotherapy for Androgen sensitive pRostate cancer patients with Lymph nodeS (Cat B, New Proposal) <i>abs# 26</i></p>	
10:25	<p>Wee Loon Ong Genitourinary (GU) Working Party update <i>abs# 27</i></p>	
10:30 - 11:00	Morning Tea & Exhibition	Concert Hall



11:00-12:30	Plenary Session: Radiobiology Chair: Eric Hau & Joseph Sia	Banquet Room
11:00	Fiona Hegi-Johnson Seeing Biology: Using novel PET tracers to develop personalised, biologically driven approaches to radiation therapy treatment <i>abs# 28</i>	
11:20	Harriet Gee Harnessing cell death mechanisms after ablative radiotherapy to enhance immunotherapy synergy <i>abs# 29</i>	
11:40	Stephen Kry Balancing data collection burden for participating centres and comprehensive utilization of clinical trial data : An NCI perspective <i>abs# 30</i>	
12:00	Timothy G Perk Machine learning simulation of targeted ablation for oligoprogressive metastatic prostate cancer <i>abs# 31</i>	
12:20	Panel Session with: Dr Fiona Hegi-Johnson, Peter MacCallum Cancer Centre; Dr Harriet Gee, Westmead Hospital; Prof Stephen Kry, MD Anderson Cancer Centre; Timothy G Perk, AIQ Solutions	
12:30 - 13:30	Lunch, Exhibition & Poster Displays	Concert Hall
13:30 - 15:00	Plenary Session: Lung Chair: Yu Yang Soon & Fiona Hehi-Johnson	Banquet Room
		Session Sponsored by:
13:30	Jane Ludbrook Moderately hypofractionated chemoradiation followed by immunotherapy for inoperable Stage 3 Non-Small Cell Lung Cancer given with radical intent in older adults (MODERN-LUNG): a randomised trial <i>abs# 32</i>	 A Siemens Healthineers Company
13:38	Margot Lehman TD 24.01 MODERN-LUNG: Discussant <i>abs# 33</i>	
13:50	Paul Keall TD 21.08 VITaL; The Ventilation Imaging for Thoracic Lung cancer radiation therapy trial (Cat C, In development) <i>abs# 34</i>	
13:54	Shankar Siva PRIME-LUNG: A randomised phase 3 trial of up-front stereotactic radiotherapy before standard-of-care systemic therapy in advanced lung cancer (Cat C, In development) <i>abs# 35</i>	
13:58	Eric Hau TD 21.09 OCTAVO; A phase II study of consolidation radiation for induced oligo-persistent disease following initial immunotherapy (Cat C, In development) <i>abs# 36</i>	




14:02	Eric Hau TROG 20.01 CHEST RT: A phase II study of carboplatin and etoposide chemotherapy, durvalumab with or without thoracic radiotherapy in the first line treatment of patients with extensive-stage small-cell lung cancer (Cat A, Open) <i>abs# 37</i>	
14:06	Yu Yang Soon TROG 17.02 OUTFUN Randomised phase II trial of Osimertinib with or without stereotactic radiosurgery for EGFR mutated NSCLC with brain metastases (Cat A, Open); Preliminary results + Cognitive Function analysis <i>abs# 38</i>	
14:10	Nicholas Bucknell Impact of SABR on Pulmonary Function: An Analysis of the TROG13.01 (SAFRON II) trial <i>abs# 39</i>	
14:18	Lucinda Burke Trial Concept Discussion; Ultracentral <i>abs# 40</i>	
14:25	Jonathan Goodwin 4D MRI for lung tumour motion assessment <i>abs# 41</i>	
14:35	Scott H Twaddell Overview of the National Lung Cancer Screening Program <i>abs# 42</i>	
14:50	Panel Discussion; Opportunities for TROG research with the implementation of National Lung Cancer Screening Program: Dr Scott Twaddell, John Hunter Hospital; Sue McCullough AM, TOGA & TROG; A/Prof Harriet Gee, Westmead Hospital; Dr Peng Seah, John Hunter Hospital	
14:55	Yu Yang Soon Lung Working Party Update <i>abs#43</i>	
15:00-15:30	Afternoon tea	Concert Hall

Notes



15:30 - 1700	Plenary Session: Health Economics & Quality of Life	Banquet Room
Chairs: Paul Keall & Shalini Vinod		
15:30	Deme Karikios Tackling financial toxicity: Isn't it just common sense? <i>abs# 44</i>	
15:50	Puma Sundaresan A new Patient Reported Measure for use in clinical trials comparing shorter fractionation with conventional schedules: measuring RT related "inconvenience" <i>abs# 45</i>	
16:00	Haryana Dhillon Symptoms in Cancer Survivorship: How patient-reported outcomes can guide intervention research <i>abs# 48</i>	
16:20	Puma Sundaresan Multidisciplinary, patient informed and patient centred research: The "problem" that informed the "Remove the mask" program of research <i>abs# 47</i>	
16:30	Youssef Y Ben Bouchta Multidisciplinary, patient informed and patient centred research: Using technology to "Remove the mask" <i>abs# 46</i>	
16:40	Panel Discussion with: Dr Deme Karikios, Nepean Cancer Car Centre A/Prof Puma Sundaresan, NSW Health A/Prof Haryana Dhillon, University of Sydney Dr Youssef Ben Bouchta, University of Sydney	

19:00 - 23:00	Gala Dinner Dress Code: Black Tie on the Beach	Sponsored by: 
---------------	--	---

Notes



Friday 15 March 2024

09:00 – 10:30	Plenary Session: Head, Neck and Skin Chairs: Charles Lin & Sweet Ping Ng	Banquet Room
	Session Sponsor:	
09:00	Danny Rischin NRG-HN014 / TD 24.02: Randomized Phase III Trial of Peri-operative Immunotherapy with Response-adjusted Surgery versus Standard-of-Care (SOC) Surgery for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) (Cat B, NewProposal) <i>abs# 49</i>	
09:15	Wen Xu MASC 03.18 / TROG 21.01 IMAT: Immunotherapy Merkel Adjuvant Trial (Cat C, Open) <i>abs# 50</i>	
09:20	Sweet Ping Ng Stereotactic radiotherapy for head and neck cancer <i>abs# 51</i>	
09:40	Stephen Kry Best way for dose accumulation assessments and/or HN SBRT QA what to watch out for <i>abs# 52</i>	
10:00	Joe Chang Radiobiological modelling of the effectiveness of stereotactic radiotherapy for head and neck cancer <i>abs# 53</i>	
10:20	Charles Lin Head, Neck and Skin (HNS) Working Party update <i>abs# 54</i>	
10:30 – 11:00	Morning Tea & Exhibition	Concert Hall

Notes



11:00 – 12:30	Plenary Session: Research Highlights & Insights	Banquet Room
Chairs: Jenna Dean & Vanessa Panettieri		
11:00	<p>Chandrima Sengupta TROG 17.03 LARK: Liver Ablative Radiotherapy utilising Kilovoltage Intrafraction Monitoring (KIM) <i>abs# 55</i></p>	
11:10	<p>David Pryor TROG 21.07 SOCRATES HCC: A randomised controlled trial of Standard Of Care versus RadioAblation in Early Stage HepatoCellular Carcinoma <i>abs# 56</i></p>	
11:20	<p>Hien Le TROG 21.12 ASPIRE: Australian Proton Therapy Clinical Quality Registry (APTCQR) <i>abs# 57</i></p>	
11:29	<p>Kelly Skelton Preliminary Insights and Development of the Australian Particle Therapy Clinical Quality Registry - ASPIRE TROG 21.12 <i>abs# 58</i></p>	
11:35	<p>Wee Loon Ong Androgen deprivation therapy and radiation therapy for prostate cancer – where are we two decades post TROG9601/TROG0304? <i>abs# 59</i></p>	
11:41	<p>Aleksandra Kazi Radiomics to predict survival in people with glioma using pre-operative imaging only: impact of volume selection for feature extraction <i>abs# 60</i></p>	
11:47	<p>Chandrima Sengupta An open-source project for managing clinical trial data: Making data accessible, usable, interoperable, and secure <i>abs# 61</i></p>	
11:53	<p>Rhonda Brown Participation in high quality audits is necessary for better cancer outcomes <i>abs# 62</i></p>	
11:59	<p>Su Chen Fong Histopathological correlation with Magnetic Resonance (MR) Imaging from MR-simulator and MR-Linac in Oesophageal and Gastric Cancers <i>abs# 63</i></p>	
12:05	<p>Joerg Lehmann Improving Patient Specific Quality Assurance – The SEAFARER Australia project <i>abs# 64</i></p>	
12:30 - 12:45	Meeting Close & Introduction to ASM 2025	Banquet Room
Joerg Lehmann & Jane Ludbrook		
12:45 - 13:30	Lunch & Exhibition	Concert Hall
Grab and go lunch boxes		

36th TROG Cancer Research
Annual Scientific Meeting

Together Towards Tomorrow

TROG 2024
12 - 15 March 2024
Newcastle NSW



PUSH THE BOUNDS OF SCIENCE MAKE LIFE-CHANGING MEDICINES

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led for 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and product candidates in development.

Learn more at www.regeneron.com/global

REGENERON[®]



POSTER LISTING

Nathaniel Barry

Computational analysis and artificial intelligence approaches for the FET PET in Glioblastoma (FIG) Trial - TROG 18.06
abs# 101

Neil D Wallace

The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small cell lung cancer abs# 102

Carrie-Anne Ng

Using conceptual frameworks to guide the selection of Patient Reported Outcome Measures in cancer clinical trials: A CQUEST Resource abs# 103

Neil D Wallace

The impact of age on survival after chemoradiotherapy for stage III NSCLC abs# 104

Ryan Motley

Deep learning-based automated assessment of prostate motion during radiotherapy treatment abs# 105

Jose A Baeza-Ortega

Clinical evaluation of a real-time treatment verification system for stereotactic body radiotherapy abs# 106

Alisha Moore

Treatment plan quality review with knowledge-based planning in the TROG 18.01 NINJA trial abs# 107

Notes



SPONSOR & EXHIBITOR PROFILES

EVENT PARTNER

Varian

www.varian.com

varian

A Siemens Healthineers Company

At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy, to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight. For more information, visit <http://www.varian.com>.

PLATINUM SPONSORS

Elekta

www.elekta.com

Elekta

As a leader in precision radiation therapy for more than 50 years and beyond, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven, and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Contact us at ANZ-Sales@elekta.com.

Icon Cancer

Centre

www.iconcancercentre.com

ICON
CANCER CENTRE

Icon Cancer Centre is part of Icon Group - Australia's largest dedicated cancer care provider. The Group has expanded globally into Singapore, Mainland China, Hong Kong and New Zealand and has a strong history of cancer research, now operating the largest private cancer clinical trials program in Australia. Icon Group has 39 cancer centres in Australia with several centres in development, including day oncology hospitals, radiation oncology facilities and comprehensive centres that bring both oncology disciplines together.

The Group also encompasses Slade Health: one of Australia's largest chemotherapy compounders with three TGA-approved manufacturing sites across the eastern seaboard; and supports Epic and Slade Pharmacy: providers of medication management and pharmacy services to the hospital and oncology sectors. For more information visit www.icongroup.global and follow us on social media @IconGroup



GOLD SPONSOR

Regeneron

www.regeneron.com

REGENERON

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for over 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For more information, please visit <https://www.regeneron.com/global> or follow Regeneron on LinkedIn

BRONZE & WELCOME RECEPTION SPONSOR

Brainlab

www.brainlab.com


 **BRAINLAB**

Brainlab is a digital medical technology pioneer founded in 1989 and headquartered in Munich. The company employs 2200 people in 25 locations around the globe. Brainlab serves physicians, medical professionals and their patients in over 6300+ hospitals in 122 countries. Brainlab creates software-driven medical solutions that digitize, automate and optimize clinical workflows for neurosurgery, spine, trauma, craniomaxillofacial (CMF), general and vascular surgery as well as radiotherapy and radiosurgery. Core products center around surgical navigation, radiotherapy, digital operating room integration, and information and knowledge exchange. Brainlab is dedicated to creating an impact in healthcare.

BRONZE SPONSORS

Australian Clinical Dosimetry Service (ACDS)

www.arpansa.gov.au



The Australian Clinical Dosimetry Service (ACDS) is a world class independent dosimetry auditing program that aims to provide a high standard of quality assurance and patient safety in radiation therapy across Australia and New Zealand. Operating since February 2011, it offers a multi-level dosimetry audit service on a four-year subscription basis to radiotherapy providers. Our comprehensive radiotherapy audit services allow benchmarking of audit results to the Australian and New Zealand dataset. The ACDS offers dosimetry audits to meet Radiation Oncology Practice Standards (ROPS), Radiation Oncology Health Program Grants (ROHPG) funding, TROG clinical trial credentialing and jurisdictional radiation licensing requirements.

AIQ Solutions

www.aiq-solutions.com



AIQ Solutions is empowering a new era of clinical decision support for Oncology.

AIQ's TRAQinform IQ is a cloud-based, machine learning-powered, software medical device that provides clinical decision support for physicians treating patients with late-stage metastatic cancer.

AIQ offers the only technology that can quantify and classify the change for each region of interest identified on PET/CT images, providing essential information helping Oncologists, Nuclear Medicine Physicians and Radiation Oncologists to make more confident treatment decisions, personalise care, and improve patient outcomes. (ARTG Code: 402321)



alpha XRT

www.alphaxrt.com



alphaXRT is Australasia's leading independent supplier of radiotherapy equipment. Our real-world experience and industry expertise help customers throughout the region in providing unparalleled patient care. We seek the very best, bringing cutting-edge equipment and specialist staff together. Our customers and their patients are our number one priority: we are deeply committed to providing all patients a future with options.

AstraZeneca

www.astrazeneca.com.au



AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

Cipla

<https://www.cipla.com/>



Cipla is a global healthcare company that strives to make a difference in the lives of patients around the world. With our focus on oncology and urology, we provide quality care for those who need it most. Our guiding principle of "Caring for Life" drives us to make a difference in every aspect of our work. With over 100 years of experience, Cipla is committed to making quality healthcare accessible to everyone.

Mundipharma Pty Limited

www.mundipharma.com



Mundipharma is committed to providing products which give people the best possible quality of life and make a difference where it matters most. Our collaborative relationships with our stakeholders are at the centre of how we operate and we take great pride in knowing that the work we do benefits healthcare professionals and their patients. With our product portfolio including Androgen Deprivation Therapy (ADT) for advanced prostate cancer, we encourage you to visit our website for healthcare professionals, <https://www.mundipharmapro.com/en-au/> where you will have access on demand to medicine information and resources for both healthcare professionals and patients.

Oxford Scientific

<https://www.oxfordscientific.com.au/>



Oxford Scientific Australia is a trusted distributor of high-value medical and scientific equipment from leading global radiotherapy manufacturers including Limbus, Standard Imaging, Xstrahl, ScandiDos, RSD and Ross Engineering.



I N T R O D U C I N G H Y P E R S I G H T ™

A REVOLUTION IN RESOLUTION

An epic advancement in
image quality, precision, and speed.

The next generation of in-treatment-room imaging:
now available for Halcyon® radiotherapy system and Ethos™ therapy.

Experience HyperSight at varian.com/hypersight

© 2023 Varian Medical Systems, Inc. All rights reserved. Varian, Varian Medical Systems, and Halcyon are registered trademarks and Ethos and HyperSight are trademarks of Varian Medical Systems, Inc. Not available for sale in all markets.

Refer enquiries to Varian Medical Systems Australasia on 1800.657.036 or customerservice-anz@varian.com

varian
A Siemens Healthineers Company